Stuart A. Arbuckle

2017

In 2017, Stuart A. Arbuckle earned a total compensation of $4.4M as EVP & Chief Commercial Officer at Vertex Pharmaceuticals, a 21% decrease compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$699,300
Option Awards$888,210
Salary$700,000
Stock Awards$2,100,013
Other$13,110
Total$4,400,633

Arbuckle received $2.1M in stock awards, accounting for 48% of the total pay in 2017.

Arbuckle also received $699.3K in non-equity incentive plan, $888.2K in option awards, $700K in salary and $13.1K in other compensation.

Rankings

In 2017, Stuart A. Arbuckle's compensation ranked 2,269th out of 14,666 executives tracked by ExecPay. In other words, Arbuckle earned more than 84.5% of executives.

ClassificationRankingPercentile
All
2,269
out of 14,666
85th
Division
Manufacturing
790
out of 5,770
86th
Major group
Chemicals And Allied Products
212
out of 2,074
90th
Industry group
Drugs
161
out of 1,730
91st
Industry
Pharmaceutical Preparations
126
out of 1,329
91st
Source: SEC filing on April 26, 2019.

Arbuckle's colleagues

We found six more compensation records of executives who worked with Stuart A. Arbuckle at Vertex Pharmaceuticals in 2017.

2017

Jeffrey Leiden

Vertex Pharmaceuticals

Chief Executive Officer

2017

Michael Parini

Vertex Pharmaceuticals

EVP & Chief Legal and Administrative Officer

2017

Ian Smith

Vertex Pharmaceuticals

Chief Operating Officer

2017

David Altshuler

Vertex Pharmaceuticals

Chief Scientific Officer

2017

Amit Sachdev

Vertex Pharmaceuticals

EVP & Chief Regulatory Officer

2017

Thomas Graney

Vertex Pharmaceuticals

Chief Financial Officer

News

You may also like